Max Planck Innovation awards license for actin marker LifeAct
Max Planck Innovation and ibidi sign license agreement for cytoskeleton research
Max-Planck-Institut für Biochemie
All higher cells depend on their cytoskeleton. This extremely flexible and highly dynamic structure gives the cells its shape, but is also an essential component in cell division as well as other fundamental processes of life. As a structural protein, actin is a component of the cytoskeleton, which can form elongated filaments that are used, among other things, as supply routes for molecular loads within the cell. Thereby, actin plays an important role in a wide array of functions such as in the development of organs and the movement of cells. Defects in the cytoskeleton are associated with various diseases such as polycystic kidney diseases and invasive tumors. Thus, the study of the cytoskeleton and in particular the study of actin is a priority in the biomedical research.
In the past, markers were available that allowed visualization of actin, but also interfered with its activity. Whereas the actin marker LifeAct, now licensed by ibidi, attaches itself to the structural protein without limiting its function. LifeAct, only 17 amino-acids long, is linked to a fluorescent dye, which makes it possible to follow the development and movement in living cells. The marker has already been used successfully in yeast cells, kidney cells, white blood cells, neuron and a variety of other cell types and tissues. A research team led by the biologists Dr. Roland Wedlich-Söldner and Dr. Michael Sixt from the Max Planck Institute of Biochemistry developed the marker. In future, ibidi will offer the peptide in various products for biological analysis. Even pathological processes where actin is involved could be decoded.
"LifeAct fits perfectly into our product portfolio with cell microscopy, immunofluorescence and cell based assays" emphasizes Dr. Valentin Kahl, founder and CEO of ibidi. "With the help of this marker, our customers can visualize and quantify the movement of cells. The new technology will be of great benefit, especially in studies of angiogenesis (the formation of blood vessels), but also in oncology, neurology, and immunology." Moreover, Dr. Mareike Göritz, patent and license manager at Max Planck Innovation, sees a great advantage in the proximity of Max Planck Institutes of Biochemistry and Neurobiology to ibidi GmbH in Martinsried: "The mutual support and uncomplicated communication should ensure a close cooperation and hence a rapid market implementation of LifeAct." This should benefit the researchers and product developers as well as the research community. Thus, LifeAct opens unprecedented opportunities to research actin as an essential component of life’s fundamental processes.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.